secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2026-07-27T23:29:38+00:00
Accession:  0001808805-26-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q2 net loss $14.5M; first revenue $0.2M; delays broadscale assay, accelerates proteoforms
--------------------------------------------------------------------------------

- Revenue of $0.2M from MJFF grant and first Early Access customer; net loss $14.5M vs $15.0M YoY.
- Operating expenses $15.9M, down 7% YoY; cash, equivalents and investments $129.2M.
- Voyager platform pre-orders expected early 2027, shipments mid-2027; proteoform kits GA mid-2027.
- Broadscale assay delayed; no 2027 GA timeline; company reallocating resources to proteoforms.
- AKT1 proteoform assay Early Access late 2026; second oncology assay mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/0001808805-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/naut-20260728.htm
  HTML page:      https://secwatch.observer/filing/0001808805-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer